Drug Class: Angiogenesis and Growth Factor/ Receptor Inhibitors

Angiogenesis Inhibitors: VEGFR

Platinum-Sensitive (Pt-S): Treatment given for recurrence occurring 6 months or more after last platinum-based treatment

Objective Response Rate (%)

Percentage of patients whose tumors shrink or go away after treatment

Progression Free Survival (months)

Median length of time before the cancer comes back or gets worse

1 Prior Therapy 2 Prior Therapies

Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment

Objective Response Rate (%)

Percentage of patients whose tumors shrink or go away after treatment

Progression Free Survival (months)

Median length of time before the cancer comes back or gets worse

2 Prior Therapies 3 Prior Therapies

Angiogenesis Inhibitors: VEGFR

Platinum-Sensitive (Pt-S): Treatment given for recurrence occurring 6 months or more after last platinum-based treatment

For more detailed information, please click on the clinical trial ID number.

Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Drugs in Clinical Development
NCT01116648 II Olaparib, Cediranib Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer

Improved ORR, PFS and OS for cediranib+olaparib combination in patients with gBRCA WT or unknown BRCA status

Ola+Ced vs Ola:

gBRCA WT or UNK:
ORR: 76 vs 32%*
PFS: 23.7 vs 5.7 months*
OS: 37.8 vs 23.0 months*

gBRCA MUT:
ORR: 83 vs 63%
PFS: 16.4 vs 16.5 months
OS: 44.2 vs 40.1 months

pub 2014; 2019

NCT02345265 II Olaparib, Cediranib A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer

Cediranib+olaparib combination is effective in Pt-S patients independent of gBRCA status

ORR: 74.3%

abs Jun 2018

*Statistically significant result

Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment

For more detailed information, please click on the clinical trial ID number.

Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Drugs in Clinical Development
NCT00275028 II Cediranib A Phase 2 Study of AZD2171 in Patients With Recurrent Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer

Cediranib has promising activity but with significant toxicity (hypertension)

ORR: 20%
PFS: 5.2 months

pub 2007

NCT02345265 II Olaparib, Cediranib A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer

Cediranib+olaparib combination shows activity in Pt-R patients

ORR: 20%

gBRCA WT:
ORR: 18%

gBRCA MUT:
ORR: 60% (n=5)

abs Jun 2018

NCT02889900; CONCERTO II Olaparib, Cediranib A Single Arm, Open-label, Phase IIb Study to Assess the Efficacy and Safety of the Combination of Cediranib and Olaparib Tablets in Women With Recurrent Platinum Resistant Epithelial Ovarian Cancer, Including Fallopian Tube and/or Primary Peritoneal Cancer Who do Not Carry a Deleterious or Suspected Deleterious Germline BRCA Mutation

Cediranib+olaparib has manageable toxicity and shows evidence of anti-tumor activity in heavily pretreated platinum resistant non-gBRCA MUT patients

ORR: 15.6%
PFS: 5.1 months

abs May 2020 and poster

NCT03314740; BAROCCO II Olaparib, Cediranib The BAROCCO Study (Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib): an Italian Multicenter Randomized Phase II Study of Weekly Paclitaxel vs. Cediranib-Olaparib With Continuous Schedule vs. Cediranib-Olaparib With Intermittent Schedule in Patients With Platinum Resistant High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

Cediranib+olaparib (continuous dosing) shows a promising trend towards improved PFS in comparison with weekly paclitaxel, in particular in BRCA WT patients

Ced+Ola (continuous) vs Ced+Ola (intermittent) vs Pac:

gBRCA WT:
PFS: 5.8 vs 3.8 vs 2.1 months

abs Oct 2019

NCT03699449 II Cediranib, Olaparib An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)

Cediranib+olaparib shows promising activity in BRCA MUT patients

ORR: 50%

abs Jun 2021 and poster

Treatment given for recurrence occurring at any time after last platinum-based treatment

For more detailed information, please click on the clinical trial ID number.

Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Drugs in Clinical Development
NCT02484404 I/II Durvalumab, Olaparib, Cediranib Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers

Promising response rates for cediranib, durvalumab and olaparib combinations in ovarian cancer

Ced+Dur: 7 evaluable
ORR: 42.9%
DCR (4 months): 71.4%

Ced+Dur+Ola: 7 evaluable
ORR: 42.9%
DCR: 71.4%
Most patients Pt-R, BRCA WT

pub 2017, pub 2019

< Return to Drug Classes

< Return to Clinical Trial Results Homepage